<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Frontiers in Neuroenergetics | New and Recent Articles</title>
        <link>https://www.frontiersin.org/journals/neuroenergetics</link>
        <description>RSS Feed for Frontiers in Neuroenergetics | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-05-14T05:44:04.834+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2014.00001</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2014.00001</link>
        <title><![CDATA[Induction of ischemic stroke in awake freely moving mice reveals that isoflurane anesthesia can mask the benefits of a neuroprotection therapy]]></title>
        <pubdate>2014-04-03T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Angela Seto</author><author>Stephanie Taylor</author><author>Dustin Trudeau</author><author>Ian Swan</author><author>Jay Leung</author><author>Patrick Reeson</author><author>Kerry R. Delaney</author><author>Craig E. Brown</author>
        <description><![CDATA[Anesthetics such as isoflurane are commonly used to sedate experimental animals during the induction of stroke. Since these agents are known to modulate synaptic excitability, inflammation and blood flow, they could hinder the development and discovery of new neuroprotection therapies. To address this issue, we developed a protocol for inducing photothrombotic occlusion of cerebral vessels in fully conscious mice and tested two potential neuroprotectant drugs (a GluN2B or α4β2 nicotinic receptor antagonist). Our data show in vehicle treated mice that just 20 min of exposure to isoflurane during stroke induction can significantly reduce ischemic cortical damage relative to mice that were awake during stroke. When comparing potential stroke therapies, none provided any level of neuroprotection if the stroke was induced with anesthesia. However, if mice were fully conscious during stroke, the α4β2 nicotinic receptor antagonist reduced ischemic damage by 23% relative to vehicle treated controls, whereas the GluN2B antagonist had no significant effect. These results suggest that isoflurane anesthesia can occlude the benefits of certain stroke treatments and warrant caution when using anesthetics for pre-clinical testing of neuroprotective agents.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00012</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00012</link>
        <title><![CDATA[Impaired cortical mitochondrial function following TBI precedes behavioral changes]]></title>
        <pubdate>2014-02-04T09:42:40.15Z</pubdate>
        <category>Original Research</category>
        
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00013</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00013</link>
        <title><![CDATA[FDG-PET imaging in mild traumatic brain injury: a critical review]]></title>
        <pubdate>2014-01-09T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Kimberly R. Byrnes</author><author>Colin M. Wilson</author><author>Fiona Brabazon</author><author>Ramona von Leden</author><author>Jennifer S. Jurgens</author><author>Terrence R. Oakes</author><author>Reed G. Selwyn</author>
        <description><![CDATA[Traumatic brain injury (TBI) affects an estimated 1.7 million people in the United States and is a contributing factor to one third of all injury related deaths annually. According to the CDC, approximately 75% of all reported TBIs are concussions or considered mild in form, although the number of unreported mild TBIs (mTBI) and patients not seeking medical attention is unknown. Currently, classification of mTBI or concussion is a clinical assessment since diagnostic imaging is typically inconclusive due to subtle, obscure, or absent changes in anatomical or physiological parameters measured using standard magnetic resonance (MR) or computed tomography (CT) imaging protocols. Molecular imaging techniques that examine functional processes within the brain, such as measurement of glucose uptake and metabolism using [18F]fluorodeoxyglucose and positron emission tomography (FDG-PET), have the ability to detect changes after mTBI. Recent technological improvements in the resolution of PET systems, the integration of PET with magnetic resonance imaging (MRI), and the availability of normal healthy human databases and commercial image analysis software contribute to the growing use of molecular imaging in basic science research and advances in clinical imaging. This review will discuss the technological considerations and limitations of FDG-PET, including differentiation between glucose uptake and glucose metabolism and the significance of these measurements. In addition, the current state of FDG-PET imaging in assessing mTBI in clinical and preclinical research will be considered. Finally, this review will provide insight into potential critical data elements and recommended standardization to improve the application of FDG-PET to mTBI research and clinical practice.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00011</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00011</link>
        <title><![CDATA[N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation]]></title>
        <pubdate>2013-12-26T00:00:00Z</pubdate>
        <category>Review</category>
        <author>John R. Moffett</author><author>Peethambaran Arun</author><author>Prasanth S. Ariyannur</author><author>Aryan M. A. Namboodiri</author>
        <description><![CDATA[N-Acetylaspartate (NAA) is employed as a non-invasive marker for neuronal health using proton magnetic resonance spectroscopy (MRS). This utility is afforded by the fact that NAA is one of the most concentrated brain metabolites and that it produces the largest peak in MRS scans of the healthy human brain. NAA levels in the brain are reduced proportionately to the degree of tissue damage after traumatic brain injury (TBI) and the reductions parallel the reductions in ATP levels. Because NAA is the most concentrated acetylated metabolite in the brain, we have hypothesized that NAA acts in part as an extensive reservoir of acetate for acetyl coenzyme A synthesis. Therefore, the loss of NAA after TBI impairs acetyl coenzyme A dependent functions including energy derivation, lipid synthesis, and protein acetylation reactions in distinct ways in different cell populations. The enzymes involved in synthesizing and metabolizing NAA are predominantly expressed in neurons and oligodendrocytes, respectively, and therefore some proportion of NAA must be transferred between cell types before the acetate can be liberated, converted to acetyl coenzyme A and utilized. Studies have indicated that glucose metabolism in neurons is reduced, but that acetate metabolism in astrocytes is increased following TBI, possibly reflecting an increased role for non-glucose energy sources in response to injury. NAA can provide additional acetate for intercellular metabolite trafficking to maintain acetyl CoA levels after injury. Here we explore changes in NAA, acetate, and acetyl coenzyme A metabolism in response to brain injury.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00010</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00010</link>
        <title><![CDATA[Concentration dependent effect of calcium on brain mitochondrial bioenergetics and oxidative stress parameters]]></title>
        <pubdate>2013-12-18T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Jignesh D. Pandya</author><author>Vidya N. Nukala</author><author>Patrick G. Sullivan</author>
        <description><![CDATA[Mitochondrial dysfunction following traumatic brain and spinal cord injury (TBI and SCI) plays a pivotal role in the development of secondary pathophysiology and subsequent neuronal cell death. Previously, we demonstrated a loss of mitochondrial bioenergetics in the first 24 h following TBI and SCI initiates a rapid and extensive necrotic event at the primary site of injury. Within the mitochondrial derived mechanisms, the cross talk and imbalance amongst the processes of excitotoxicity, Ca2+ cycling/overload, ATP synthesis, free radical production and oxidative damage ultimately lead to mitochondrial damage followed by neuronal cell death. Mitochondria are one of the important organelles that regulate intracellular calcium (Ca2+) homeostasis and are equipped with a tightly regulated Ca2+ transport system. However, owing to the lack of consensus and the link between downstream effects of calcium in published literature, we undertook a systematic in vitro study for measuring concentration dependent effects of calcium (100–1000 nmols/mg mitochondrial protein) on mitochondrial respiration, enzyme activities, reactive oxygen/nitrogen species (ROS/RNS) generation, membrane potential (ΔΨ) and oxidative damage markers in isolated brain mitochondria. We observed a dose- and time-dependent inhibition of mitochondrial respiration by calcium without influencing mitochondrial pyruvate dehydrogenase complex (PDHC) and NADH dehydrogenase (Complex I) enzyme activities. We observed dose-dependent decreased production of hydrogen peroxide and total ROS/RNS species generation by calcium and no significant changes in protein and lipid oxidative damage markers. These results may shed new light on the prevailing dogma of the direct effects of calcium on mitochondrial bioenergetics, free radical production and oxidative stress parameters that are primary regulatory mitochondrial mechanisms following neuronal injury.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00009</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00009</link>
        <title><![CDATA[13C NMR spectroscopy applications to brain energy metabolism]]></title>
        <pubdate>2013-12-09T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Tiago B. Rodrigues</author><author>Julien Valette</author><author>Anne-Karine Bouzier-Sore</author>
        <description><![CDATA[13C nuclear magnetic resonance (NMR) spectroscopy is the method of choice for studying brain metabolism. Indeed, the most convincing data obtained to decipher metabolic exchanges between neurons and astrocytes have been obtained using this technique, thus illustrating its power. It may be difficult for non-specialists, however, to grasp thefull implication of data presented in articles written by spectroscopists. The aim of the review is, therefore, to provide a fundamental understanding of this topic to facilitate the non-specialists in their reading of this literature. In the first part of this review, we present the metabolic fate of 13C-labeled substrates in the brain in a detailed way, including an overview of some general neurochemical principles. We also address and compare the various spectroscopic strategies that can be used to study brain metabolism. Then, we provide an overview of the 13C NMR experiments performed to analyze both intracellular and intercellular metabolic fluxes. More particularly, the role of lactate as a potential energy substrate for neurons is discussed in the light of 13C NMR data. Finally, new perspectives and applications offered by 13C hyperpolarization are described.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00008</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00008</link>
        <title><![CDATA[Insights into the metabolic response to traumatic brain injury as revealed by 13C NMR spectroscopy]]></title>
        <pubdate>2013-10-04T00:00:00Z</pubdate>
        <category>Mini Review</category>
        <author>Brenda L. Bartnik-Olson</author><author>Neil G. Harris</author><author>Katsunori Shijo</author><author>Richard L. Sutton</author>
        <description><![CDATA[The present review highlights critical issues related to cerebral metabolism following traumatic brain injury (TBI) and the use of 13C labeled substrates and nuclear magnetic resonance (NMR) spectroscopy to study these changes. First we address some pathophysiologic factors contributing to metabolic dysfunction following TBI. We then examine how 13C NMR spectroscopy strategies have been used to investigate energy metabolism, neurotransmission, the intracellular redox state, and neuroglial compartmentation following injury. 13C NMR spectroscopy studies of brain extracts from animal models of TBI have revealed enhanced glycolytic production of lactate, evidence of pentose phosphate pathway (PPP) activation, and alterations in neuronal and astrocyte oxidative metabolism that are dependent on injury severity. Differential incorporation of label into glutamate and glutamine from 13C labeled glucose or acetate also suggest TBI-induced adaptations to the glutamate-glutamine cycle.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00007</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00007</link>
        <title><![CDATA[Natural selection of mitochondria during somatic lifetime promotes healthy aging]]></title>
        <pubdate>2013-08-12T00:00:00Z</pubdate>
        <category>Perspective</category>
        <author>Anders Rodell</author><author>Lene J. Rasmussen</author><author>Linda H. Bergersen</author><author>Keshav K. Singh</author><author>Albert Gjedde</author>
        <description><![CDATA[Stimulation of mitochondrial biogenesis during life-time challenges both eliminates disadvantageous properties and drives adaptive selection of advantageous phenotypic variations. Intermittent fission and fusion of mitochondria provide specific targets for health promotion by brief temporal stressors, interspersed with periods of recovery and biogenesis. For mitochondria, the mechanisms of selection, variability, and heritability, are complicated by interaction of two independent genomes, including the multiple copies of DNA in each mitochondrion, as well as the shared nuclear genome of each cell. The mechanisms of stress-induced fission, followed by recovery-induced fusion and biogenesis, drive the improvement of mitochondrial functions, not only as directed by genotypic variations, but also as enabled by phenotypic diversity. Selective adaptation may explain unresolved aspects of aging, including the health effects of exercise, hypoxic and poisonous preconditioning, and tissue-specific mitochondrial differences. We propose that intermittent purposeful enhancement of mitochondrial biogenesis by stressful episodes with subsequent recovery paradoxically promotes adaptive mitochondrial health and continued healthy aging.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00006</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00006</link>
        <title><![CDATA[Hypothalamic metabolic compartmentation during appetite regulation as revealed by magnetic resonance imaging and spectroscopy methods]]></title>
        <pubdate>2013-06-13T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Blanca Lizarbe</author><author>Ania Benitez</author><author>Gerardo A. Peláez Brioso</author><author>Manuel Sánchez-Montañés</author><author>Pilar López-Larrubia</author><author>Paloma Ballesteros</author><author>Sebastián Cerdán</author>
        <description><![CDATA[We review the role of neuroglial compartmentation and transcellular neurotransmitter cycling during hypothalamic appetite regulation as detected by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) methods. We address first the neurochemical basis of neuroendocrine regulation in the hypothalamus and the orexigenic and anorexigenic feed-back loops that control appetite. Then we examine the main MRI and MRS strategies that have been used to investigate appetite regulation. Manganese-enhanced magnetic resonance imaging (MEMRI), Blood oxygenation level-dependent contrast (BOLD), and Diffusion-weighted magnetic resonance imaging (DWI) have revealed Mn2+ accumulations, augmented oxygen consumptions, and astrocytic swelling in the hypothalamus under fasting conditions, respectively. High field 1H magnetic resonance in vivo, showed increased hypothalamic myo-inositol concentrations as compared to other cerebral structures. 1H and 13C high resolution magic angle spinning (HRMAS) revealed increased neuroglial oxidative and glycolytic metabolism, as well as increased hypothalamic glutamatergic and GABAergic neurotransmissions under orexigenic stimulation. We propose here an integrative interpretation of all these findings suggesting that the neuroendocrine regulation of appetite is supported by important ionic and metabolic transcellular fluxes which begin at the tripartite orexigenic clefts and become extended spatially in the hypothalamus through astrocytic networks becoming eventually MRI and MRS detectable.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00005</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00005</link>
        <title><![CDATA[Glucose and lactate metabolism in the awake and stimulated rat: a 13C-NMR study]]></title>
        <pubdate>2013-05-31T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Denys Sampol</author><author>Eugène Ostrofet</author><author>Marie-Lise Jobin</author><author>Gérard Raffard</author><author>Stéphane Sanchez</author><author>Véronique Bouchaud</author><author>Jean-Michel Franconi</author><author>Gilles Bonvento</author><author>Anne-Karine Bouzier-Sore</author>
        <description><![CDATA[Glucose is the major energetic substrate for the brain but evidence has accumulated during the last 20 years that lactate produced by astrocytes could be an additional substrate for neurons. However, little information exists about this lactate shuttle in vivo in activated and awake animals. We designed an experiment in which the cortical barrel field (S1BF) was unilaterally activated during infusion of both glucose and lactate (alternatively labeled with 13C) in rats. At the end of stimulation (1 h) both S1BF areas were removed and analyzed by HR-MAS NMR spectroscopy to compare glucose and lactate metabolism in the activated area vs. the non-activated one. In combination with microwave irradiation HR-MAS spectroscopy is a powerful technical approach to study brain lactate metabolism in vivo. Using in vivo14C-2-deoxyglucose and autoradiography we confirmed that whisker stimulation was effective since we observed a 40% increase in glucose uptake in the activated S1BF area compared to the ipsilateral one. We first determined that lactate observed on spectra of biopsies did not arise from post-mortem metabolism. 1H-NMR data indicated that during brain activation there was an average 2.4-fold increase in lactate content in the activated area. When [1-13C]glucose + lactate were infused 13C-NMR data showed an increase in 13C-labeled lactate during brain activation as well as an increase in lactate C3-specific enrichment. This result demonstrates that the increase in lactate observed on 1H-NMR spectra originates from newly synthesized lactate from the labeled precursor ([1-13C]glucose). It also shows that this additional lactate does not arise from an increase in blood lactate uptake since it would otherwise be unlabeled. These results are in favor of intracerebral lactate production during brain activation in vivo which could be a supplementary fuel for neurons.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00004</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00004</link>
        <title><![CDATA[Astroglial networking contributes to neurometabolic coupling]]></title>
        <pubdate>2013-04-26T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Carole Escartin</author><author>Nathalie Rouach</author>
        <description><![CDATA[The strategic position of astrocytic processes between blood capillaries and neurons, provided the early insight that astrocytes play a key role in supplying energy substrates to neurons in an activity-dependent manner. The central role of astrocytes in neurometabolic coupling has been first established at the level of single cell. Since then, exciting recent work based on cellular imaging and electrophysiological recordings has provided new mechanistic insights into this phenomenon, revealing the crucial role of gap junction (GJ)-mediated networks of astrocytes. Indeed, astrocytes define the local availability of energy substrates by regulating blood flow. Subsequently, in order to efficiently reach distal neurons, these substrates can be taken up, and distributed through networks of astrocytes connected by GJs, a process modulated by neuronal activity. Astrocytic networks can be morphologically and/or functionally altered in the course of various pathological conditions, raising the intriguing possibility of a direct contribution from these networks to neuronal dysfunction. The present review upgrades the current view of neuroglial metabolic coupling, by including the recently unravelled properties of astroglial metabolic networks and their potential contribution to normal and pathological neuronal activity.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00003</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00003</link>
        <title><![CDATA[Neurophysiological, metabolic and cellular compartments that drive neurovascular coupling and neuroimaging signals]]></title>
        <pubdate>2013-03-28T00:00:00Z</pubdate>
        <category>Mini Review</category>
        <author>Andrea Moreno</author><author>Pierrick Jego</author><author>Feliberto de la Cruz</author><author>Santiago Canals</author>
        <description><![CDATA[Complete understanding of the mechanisms that coordinate work and energy supply of the brain, the so called neurovascular coupling, is fundamental to interpreting brain energetics and their influence on neuronal coding strategies, but also to interpreting signals obtained from brain imaging techniques such as functional magnetic resonance imaging. Interactions between neuronal activity and cerebral blood flow regulation are largely compartmentalized. First, there exists a functional compartmentalization in which glutamatergic peri-synaptic activity and its electrophysiological events occur in close proximity to vascular responses. Second, the metabolic processes that fuel peri-synaptic activity are partially segregated between glycolytic and oxidative compartments. Finally, there is cellular segregation between astrocytic and neuronal compartments, which has potentially important implications on neurovascular coupling. Experimental data is progressively showing a tight interaction between the products of energy consumption and neurotransmission-driven signaling molecules that regulate blood flow. Here, we review some of these issues in light of recent findings with special attention to the neuron-glia interplay on the generation of neuroimaging signals.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00002</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00002</link>
        <title><![CDATA[Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain]]></title>
        <pubdate>2013-03-27T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Michael Gejl</author><author>Susanne Lerche</author><author>Lærke Egefjord</author><author>Birgitte Brock</author><author>Niels Møller</author><author>Kim Vang</author><author>Anders B. Rodell</author><author>Bo M. Bibby</author><author>Jens J. Holst</author><author>Jørgen Rungby</author><author>Albert Gjedde</author>
        <description><![CDATA[In hyperglycemia, glucagon-like peptide-1 (GLP-1) lowers brain glucose concentration together with increased net blood-brain clearance and brain metabolism, but it is not known whether this effect depends on the prevailing plasma glucose (PG) concentration. In hypoglycemia, glucose depletion potentially impairs brain function. Here, we test the hypothesis that GLP-1 exacerbates the effect of hypoglycemia. To test the hypothesis, we determined glucose transport and consumption rates in seven healthy men in a randomized, double-blinded placebo-controlled cross-over experimental design. The acute effect of GLP-1 on glucose transfer in the brain was measured by positron emission tomography (PET) during a hypoglycemic clamp (3 mM plasma glucose) with 18F-fluoro-2-deoxy-glucose (FDG) as tracer of glucose. In addition, we jointly analyzed cerebrometabolic effects of GLP-1 from the present hypoglycemia study and our previous hyperglycemia study to estimate the Michaelis-Menten constants of glucose transport and metabolism. The GLP-1 treatment lowered the vascular volume of brain tissue. Loading data from hypo- to hyperglycemia into the Michaelis-Menten equation, we found increased maximum phosphorylation velocity (Vmax) in the gray matter regions of cerebral cortex, thalamus, and cerebellum, as well as increased blood-brain glucose transport capacity (Tmax) in gray matter, white matter, cortex, thalamus, and cerebellum. In hypoglycemia, GLP-1 had no effects on net glucose metabolism, brain glucose concentration, or blood-brain glucose transport. Neither hexokinase nor transporter affinities varied significantly with treatment in any region. We conclude that GLP-1 changes blood-brain glucose transfer and brain glucose metabolic rates in a PG concentration-dependent manner. One consequence is that hypoglycemia eliminates these effects of GLP-1 on brain glucose homeostasis.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2013.00001</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2013.00001</link>
        <title><![CDATA[Modeling the glutamate–glutamine neurotransmitter cycle]]></title>
        <pubdate>2013-01-28T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Jun Shen</author>
        <description><![CDATA[Glutamate is the principal excitatory neurotransmitter in brain. Although it is rapidly synthesized from glucose in neural tissues the biochemical processes for replenishing the neurotransmitter glutamate after glutamate release involve the glutamate–glutamine cycle. Numerous in vivo13C magnetic resonance spectroscopy (MRS) experiments since 1994 by different laboratories have consistently concluded: (1) the glutamate–glutamine cycle is a major metabolic pathway with a flux rate substantially greater than those suggested by early studies of cell cultures and brain slices; (2) the glutamate–glutamine cycle is coupled to a large portion of the total energy demand of brain function. The dual roles of glutamate as the principal neurotransmitter in the CNS and as a key metabolite linking carbon and nitrogen metabolism make it possible to probe glutamate neurotransmitter cycling using MRS by measuring the labeling kinetics of glutamate and glutamine. At the same time, comparing to non-amino acid neurotransmitters, the added complexity makes it more challenging to quantitatively separate neurotransmission events from metabolism. Over the past few years our understanding of the neuronal-astroglial two-compartment metabolic model of the glutamate–glutamine cycle has been greatly advanced. In particular, the importance of isotopic dilution of glutamine in determining the glutamate–glutamine cycling rate using [1−13C] or [1,6-13C2] glucose has been demonstrated and reproduced by different laboratories. In this article, recent developments in the two-compartment modeling of the glutamate–glutamine cycle are reviewed. In particular, the effects of isotopic dilution of glutamine on various labeling strategies for determining the glutamate–glutamine cycling rate are analyzed. Experimental strategies for measuring the glutamate–glutamine cycling flux that are insensitive to isotopic dilution of glutamine are also suggested.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2012.00010</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2012.00010</link>
        <title><![CDATA[Inter-Trial Variability in Sensory-Evoked Cortical Hemodynamic Responses: The Role of the Magnitude of Pre-Stimulus Fluctuations]]></title>
        <pubdate>2012-11-05T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Mohamad Saka</author><author>Jason Berwick</author><author>Myles Jones</author>
        <description><![CDATA[Brain imaging techniques utilize hemodynamic changes that accompany brain activation. However, stimulus-evoked hemodynamic responses display considerable inter-trial variability and the sources of this variability are poorly understood. One of the sources of this response variation could be ongoing spontaneous hemodynamic fluctuations. We recently investigated this issue by measuring cortical hemodynamics in response to sensory stimuli in anesthetized rodents using 2-dimensional optical imaging spectroscopy. We suggested that sensory-evoked cortical hemodynamics displayed distinctive response characteristics and magnitudes depending on the phase of ongoing fluctuations at stimulus onset due to a linear superposition of evoked and ongoing hemodynamics (Saka et al., 2010). However, the previous analysis neglected to examine the possible influence of variability of the size of ongoing fluctuations. Consequently, data were further analyzed to examine whether the size of pre-stimulus hemodynamic fluctuations also influenced the magnitude of subsequent stimulus-evoked responses. Indeed, in the case of all individual trials, a moderate correlation between the size of the pre-stimulus fluctuations and the magnitudes of the subsequent sensory-evoked responses were observed. However, different correlations between the size of the pre-stimulus fluctuations and magnitudes of the subsequent sensory-evoked cortical hemodynamic responses could be observed depending on their phase at stimulus onset. These analyses suggest that both the size and phase of pre-stimulus fluctuations in cortical hemodynamics contribute to inter-trial variability in sensory-evoked responses.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2012.00009</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2012.00009</link>
        <title><![CDATA[Understanding How the Brain Ensures Its Energy Supply]]></title>
        <pubdate>2012-08-20T00:00:00Z</pubdate>
        <category>Editorial</category>
        <author>Yuri Zilberter</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2012.00008</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2012.00008</link>
        <title><![CDATA[Low Residual CBF Variability in Alzheimer’s Disease after Correction for CO2 Effect]]></title>
        <pubdate>2012-07-05T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Anders Bertil Rodell</author><author>Joel Aanerud</author><author>Hans Braendgaard</author><author>Albert Gjedde</author>
        <description><![CDATA[We tested the claim that inter-individual CBF variability in Alzheimer’s disease (AD) is substantially reduced after correction for arterial carbon dioxide tension (PaCO2). Specifically, we tested whether the variability of CBF in brain of patients with AD differed significantly from brain of age-matched healthy control subjects (HC). To eliminate the CO2-induced variability, we developed a novel and generally applicable approach to the correction of CBF for changes of PaCO2 and applied the method to positron emission tomographic (PET) measures of CBF in AD and HC groups of subjects. After correction for the differences of CO2 tension, the patients with AD lost the inter-individual CBF variability that continued to characterize the HC subjects. The difference (ΔK1) between the blood-brain clearances (K1) of water (the current measure of CBF) and oxygen (the current measure of oxygen clearance) was reduced globally in AD and particularly in the parietal, occipital, and temporal lobes. We then showed that oxygen gradients calculated for brain tissue were similar in AD and HC, indicating that the low residual variability of CBF in AD may be due to low functional demands for oxidative metabolism of brain tissue rather than impaired delivery of oxygen.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2012.00007</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2012.00007</link>
        <title><![CDATA[Food Addiction and Obesity: Do Macronutrients Matter?]]></title>
        <pubdate>2012-05-30T00:00:00Z</pubdate>
        <category>General Commentary</category>
        <author>Tanya Zilberter</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2012.00006</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2012.00006</link>
        <title><![CDATA[Image Quality Analysis of High-Density Diffuse Optical Tomography Incorporating a Subject-Specific Head Model]]></title>
        <pubdate>2012-05-24T00:00:00Z</pubdate>
        <category>Original Research</category>
        
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fnene.2012.00005</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fnene.2012.00005</link>
        <title><![CDATA[Is lactate a volume transmitter of metabolic states of the brain?]]></title>
        <pubdate>2012-03-19T00:00:00Z</pubdate>
        <category>Perspective</category>
        <author>Linda H. Bergersen</author><author>Albert Gjedde</author>
        <description><![CDATA[We present the perspective that lactate is a volume transmitter of cellular signals in brain that acutely and chronically regulate the energy metabolism of large neuronal ensembles. From this perspective, we interpret recent evidence to mean that lactate transmission serves the maintenance of network metabolism by two different mechanisms, one by regulating the formation of cAMP via the lactate receptor GPR81, the other by adjusting the NADH/NAD+ redox ratios, both linked to the maintenance of brain energy turnover and possibly cerebral blood flow. The role of lactate as mediator of metabolic information rather than metabolic substrate answers a number of questions raised by the controversial oxidativeness of astrocytic metabolism and its contribution to neuronal function.]]></description>
      </item>
      </channel>
    </rss>